London Markets: U.K. stocks fall from record as AstraZeneca, oil stocks decline

This post was originally published on this site

U.K. stocks on Friday pulled back from a record close, as shares of AstraZeneca declined following the heavyweight drug maker’s earnings report, and as shares in oil companies took a break from their recent rally.

What are markets doing?

The FTSE 100 index UKX, -0.20%  dropped 0.2% to 7,775.70, on track to break a three-day winning streak. On Thursday, that win streak helped push the London benchmark to an all-time closing high, after a solid run that was boosted by a weaker pound and a rally in oil stocks.

For the week, the FTSE 100 was on track for a 0.6% gain, which would mark an eighth straight week of advances. That would be its longest weekly winning run since July 2005, when the index also rose for eight consecutive weeks.

The pound GBPUSD, -0.1554%  on Friday fell to $1.3512 from $1.3516 late Thursday in New York.

What is driving the market?

U.K. investors paused for breath after pushing the blue-chip index to a record on Thursday. They also monitored geopolitical risks and the latest developments in the Brexit discussions.

On the Brexit front, U.K. Prime Minister Theresa May denied reports earlier this week that Britain was looking to stay in the EU customs union after Brexit. Instead, her cabinet agreed to a “backstop” proposal that would align the U.K. with EU tariffs after 2020 to avoid a hard border with Ireland. The backstop plan would only be needed if the U.K. was unable to agree on a separate customs deal with the EU, which would raise prospect of a hard border in Ireland, according to the BBC.

On the global scene, U.S. President Donald Trump somewhat dashed hopes of a trade deal between the U.S. and China. At a press conference on Thursday, Trump said he doubts that the negotiations will succeed because “China has become very spoiled” on trade.

With no major economic reports on deck in the U.K. on Friday, traders instead focused on the latest corporate news.

Stock movers

Shares of AstraZeneca PLC AZN, -2.56% AZN, -0.16%  dropped 1.8% after the pharma giant reported core earnings that missed forecasts. Core operating profit — the company’s preferred measure, which strips out one-time gains and impairments — fell to $896 million from $1.67 billion a year ago.

J Sainsbury PLC SBRY, -0.13%  rose 0.2%. The gain came even as the U.K. competition watchdog said it is considering investigating the proposed merger between J Sainsbury PLC and Walmart Inc.’s WMT, -1.90%  British arm, Asda Group Ltd.

Energy companies were also falling after scoring multi-year highs on Thursday on the back of a continued advance in oil prices. Shares of BP PLC BP., -0.19% BP, +1.03%  , which closed at an eight-year high on Thursday, dropped 0.3% on Friday, while Royal Dutch Shell PLC RDSB, -0.53% RDS.B, +1.61%  , which scored an all-time high on Thursday, fell 0.5%.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.